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There is a wide range of variability in the clinical phenotype of Sickle Cell Disease (SCD), 
resulting in a vast array of clinical presentations ranging from acute, recurrent vaso-occlusive 
pain episodes to chronic pain, increased risk of strokes, acute chest syndromes and osteonecrosis.  
Historically, pain crises have been defined by whether or not the patient seeks medical attention.  
Previous studies have shown that while patients with SCD are in pain 54.5% of the time, they 
are only seeking medical attention during 3.5% of these episodes. This has led to a gross 
underestimation of the prevalence of pain episodes, due to discrepancies in both the definition 
and reporting of these episodes.  There is currently no utility available to accurately assess and 
manage pain levels in Sickle Cell patients who are not utilizing medical facilities. The 
implementation of a web-based application to monitor daily pain levels is relevant to public 
health because it is likely to provide medical teams with the tools necessary to track patient pain 
levels more precisely. This will also enable healthcare providers to be more proactive with 
regard to pain management in patients with SCD. 
Twenty-nine patients were asked to record their level of pain three times daily for six 
months via a web-based application.  The application asked patients to appraise their pain level 
by use of a Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (extreme pain).  Each 
patient was assigned a non-specific identifier that enabled him or her to log into the system 
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without referencing any personal health information.   Pain measurements were electronically 
time stamped and all information was filtered to ensure the protection of patient sensitive 
information. Authorized team members were alerted of pain episodes by email (pain levels of 5- 
7) or text message (pain levels of 8-10). The patient was then contacted and information was 
gathered regarding the location and duration of pain, the presence of other symptoms and social 
factors that influenced a patient’s decision to seek medical intervention. 
Of the 29 patients enrolled in the study, 21 patients accessed the web-based application 
and provided a total of 4,981 pain data entries over a six month time period.  Patients reported 
that they were in no pain (pain score of 0) 23.4% of the days logged, in pain (pain score of 1-7) 
76.6% of the days logged and in pain crisis (pain score of 8-10) 12.2% of the days logged. 
 
This  data  provides  proof  of  the  principle  that  adolescents  with  SCD  will  provide 
electronic reports of their pain multiple times a day over an extended period of time. This 
preliminary data also suggests that the prevalence of pain in adolescents is much greater than 
previously reported. 
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1.0  INTRODUCTION 
Sickle Cell Disease (SCD) is one of the most common monogenic disorders worldwide4.  SCD 
predominately affects individuals of African ancestry, where 1 in 8 are carriers of this condition.  
However, SCD can also affect persons of Mediterranean, Arabian, East Indian, South and 
Central American and Caribbean ancestry.  In the United States alone, more than 1,100 infants 
are born each year with this condition1,4.  
SCD is characterized by acute, recurrent, vaso-occlusive pain episodes that often present 
within the first 1-2 years of life5.  These vaso-occlusive pain episodes, termed vaso-occlusive 
crises (VOC), are the leading cause of morbidity and mortality associated with SCD.  This is due 
to the fact that VOC results in a wide range of clinical manifestations such as: bone marrow 
infarctions, splenic sequestration, organ damage and cerebrovascular accidents (stroke)5. 
Historically, the medical community has defined a pain episode based on healthcare 
utilization.  However, studies have shown that while patients with SCD are in pain 54.5% of the 
time, they only seek medical attention for 3.5% of these episodes3,6.  This has led to a gross 
underestimation of the prevalence of pain episodes due to discrepancies in both the definition 
and reporting of pain episodes.  There is currently no tool available to accurately assess and 
manage pain levels in Sickle Cell patients who are not utilizing medical facilities.  
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The purpose of this study is to determine whether the implementation of a web-based 
application can be used to more precisely monitor a patient’s daily pain level. Healthcare 
providers may become more proactive with regard to pain management in Sickle Cell patients if 
daily pain levels are known. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 SICKLE CELL DISEASE 
SCD is an autosomal recessive inherited hemoglobinopathy that was first described by physician 
James Herrick, in 1910, when he noted the presence of a “large number of thin, elongated, 
sickle-shaped and crescent-shaped” red blood cells in a young Grenadian patient’s blood smear7.  
In 1949, Linus Pauling et al. were the first to suggest that the cause of SCD was the result of 
defective hemoglobin molecules8. 
Hemoglobin (Hb) is tetrameric protein composed of two alpha (α) and two beta (β) 
globin polypeptide chains9.  The conformation of these 4 polypeptide chains provides a 
protective central space that enables hemoglobin to noncovalently bind to the iron-protopohyrin 
IX molecule, heme, without exposing it to the surrounding aqueous cellular environment9.  The 
presence of the heme molecule enables hemoglobin to transiently bind and transport O2, CO2, 
CO and NO9.  The presence of high concentrations of these hemoglobin molecules allows the red 
blood cells to efficiently transport oxygen from the lungs to all the cells of the body.  
The α-globin like genes located on chromosome 16 encode the embryonic ζ-globin and 
the adult α-globin molecules9.  The β-globin like genes located on chromosome 11 encode the 
embryonic ε-globin, fetal γ-globin and adult δ-globin and β-globin molecules9.  The expression 
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of various α- and β-globin molecules change over the course of an individual’s lifetime (Figure 
1)9.  
 
             Figure 1:Genetic Expression of Human Hemoglobin9 
During the early stages of embryogenesis the ζ and ε globin genes are expressed to form 
Hb Gower 19.  As the embryo continues to grow there is a decrease in the expression of the ζ and 
ε globin genes and an increase in the expression of the α-, Gγ- and Aγ- globin genes9.  This 
results in the formation of two additional embryonic hemoglobin molecules Hb Gower 2, 
consisting of α2ε2 and Hb Portland, consisting of ζ2γ29.  As the concentration of α- and γ-globin 
molecules increases, Hb Gower 2 and Hb Portland are eventually replaced with fetal hemoglobin 
molecules, consisting of α2Aγ2 or α2Gγ29.  
After birth, the expression of Gγ- and Aγ- globin genes are replaced by the expression of 
β- and δ- globin genes leading to the formation of the adult hemoglobin molecules Hb A and Hb 
A29.  Hemoglobin A consists of α2β2 and accounts for 97% of the hemoglobin molecules found 
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in the adult human body while Hb A2 consisting of α2δ2 accounts for 2% of the hemoglobin 
molecules in the human body9.  
 
2.1.1 Variant Forms of Sickle Cell Disease 
Table 1: Variant Forms of Beta-Globin4,10  
Hemoglobin Description 
HbS β6 Glutamic acid (GAG)? Valine (GTG) 
HbC β6 Glutamic acid (GAG)? Lysine (AAG) 
Hb D Punjab β121 Glutamine (GAG)? Glutamic acid (GAG) 
Hb O Arab β121 Glutamine (GAG)? Lysine (AAG) 
βo Thalassemia 
Complete lack of Hb A due to the inability to 
produce a normal β-chain  
β+ Thalassemia 
Production of a reduced amount of β-chain leads to 
variable amount of Hb A  
HPFH α2γ2 
 
The term Sickle Cell Disease is used to describe a broad range of hemoglobinopathies 
that are characterized by Hb S in the presence of another variant beta globin chain (Table 1)4,10. 
The majority of the cases of SCD are composed of four primary subtypes: SS, SC, Sβo and Sβ+. 
Less frequently, cases of Sickle Cell-Hb D Punjab and Sickle Cell-Hb O Arab have been 
reported4,10.  
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2.2 MOLECULAR BASIS OF SICKLE CELL DISEASE 
In 1957, the genetic basis of SCD was identified as a single nucleotide substitution of thymine 
for adenine in the sixth codon of the β-hemoglobin gene6,8.  This change results in the 
translational substitution of the polar, hydrophilic, glutamic acid with the nonpolar, hydrophobic 
valine 6,8.   
As red blood cells circulate and become deoxygenated, the HbS molecules undergo a 
conformational change that exposes the hydrophobic Valine residue8,12. The exposed 
hydrophobic regions of adjacent HbS molecules polymerize in the aqueous compartment of the 
cell.  This polymerization of HbS results in the formation of rigid fibers that damage the 
cytoskeleton of the red blood cell increase cell permeability and cause the hallmark “sickled” 
appearance8,12. As the RBC becomes re-oxygenated it results in the dissociation of the Hb S 
fibers and the RBC reverts to the  standard biconcave disc shape8.   
With each pass through the circulatory system, the red blood cell becomes increasingly 
more damaged. Increases in cell permeability result in the dehydration of the RBC thereby 
increase cellular viscosity and perpetuate further polymerization of Hb S molecules. As cellular 
damage continues, the RBC begins to express adhesion molecules and receptors that enable the 
RBC to adhere to circulating White blood cells (WBCs) and the cellular endothelium8. The 
presence of sickled RBCs, as well as their adherence to other cellular entities, results in a 
decrease in the velocity of the circulating blood. All of these factors combined lead to an 
increase in the likelihood of cellular adhesions that can ultimately result in the occlusion of 
micro- or microvasculature, known as vaso-occlusive crisis (VOC).  These vaso-occlusive events 
are the hallmark characteristic of SCD and are responsible for most of the severe clinical 
manifestations of SCD13. 
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2.3 INHERITANCE 
SCD is inherited in an autosomal recessive manner1,10. This means that an individual will 
develop SCD when they inherit one Hb S gene from one parent and any other variant β-globin 
gene from the other parent (Table 1).  When both parents have a Hb S gene the risk for having a 
child with SCD is 1 in 4 or 25% 1,10.  
 
2.4 CLINICAL MANIFESTATIONS 
The physiological changes, chronic hemolytic anemia and immunologic impairment associated 
with Hb S can lead to systemic damage, resulting in wide a range of phenotypic manifestations.  
2.4.1 Hand-Foot Syndrome 
Dactylitis, commonly referred to as Hand-Foot syndrome, is characterized by painful swelling of 
the hands and feet that generally resolves within one week10,12,14. This is one of the earliest 
complications of SCD with the highest incidence occurring between 6 months to 2 years of life. 
Studies have shown that a history of early onset dactylitis (prior to 6 months of age) serves as an 
indicator of severe disease manifestations later in life14.  
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2.4.2 Acute Chest Syndrome 
Acute Chest Syndrome (ACS) is characterized by infiltration of the pulmonary vasculature with 
sickled RBCs12.  ACS is associated with: lower respiratory symptoms such as chest and/or 
abdominal pain, shortness of breath and fever; hypoxemia; and radiological findings that mimic 
pneumonia on chest X-ray1,4. ACS is the second most common cause of hospitalizations in SCD 
occurring in 40% of patients and is a major cause (25%) of death in childhood1,4,15.  ACS often 
develops during a vaso-occlusive event and is the result of a combination of factors such as: 
bacterial or viral infection, VOC of the pulmonary vasculature, pulmonary infarction, or the 
presence of a fat/bone marrow or sickled RBC emboli1,5,12. 
2.4.3 Hemolytic Anemia 
Hemolytic anemia is evident beginning within the first year of life.  The physiological changes 
and cellular damage associated with Hb S reduce the lifespan of a RBC from 90-120 days to 10-
20 days5.  The rate of erythropoiesis is increased to compensate for the peripheral destruction of 
RBCs. This leads to an increase in the amount of RBC precursors within the bone marrow and 
the introduction of immature reticulocytes into the blood stream5.  The increased rate of 
hemolysis also results in the accumulation of indirect (unconjugated) bilirubin5. High levels of 
indirect bilirubin are responsible for the increased prevalence of jaundice and gall stones seen in 
SCD patients5.   
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2.4.4 Infection 
Infections are a major cause of morbidity and mortality in SCD. Studies have shown that 
infections have been linked to 20-50% of all deaths reported in prospective cohort studies over 
the past 20 years15. Impaired splenic functioning, tissue ischaemia, micronutrient deficiencies 
and defects in the activation of the complement pathway, are believed to result in an increased 
risk of bacterial and viral infections. Streptococcus, pneumonia, influenzae, salmonellae, malaria, 
hepatitis, parvovirus and chlamydophila are the most commonly reported infections reported in 
SCD patients4,15. 
2.4.5 Pulmonary Hypertension 
Approximately 33% of adult patients suffer from pulmonary hypertension as a result of damage 
to the pulmonary vasculature16,17.  High blood pressure in the lungs is a major risk factor for 
death in SCD and greatly increases the mortality rate in SCD patients16,17. 
 
2.4.6 Splenic Sequestration 
Splenic sequestration is a life threatening condition that is most common in the first 5 years of 
life but can be seen at any age in patients with Hb SC or Hb Sβ thalassemia18. Splenic 
sequestration may be associated with fever, pain and respiratory problems.  Sequestration is 
characterized by the sudden entrapment of blood within the spleen resulting in the rapid onset of 
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severe anemia and enlargement of the spleen18. If left untreated, this can result in circulatory 
collapse and death in less than thirty minutes. 
2.4.7 Renal Involvement 
The renal micro-environment promotes Hb S polymerization due to low partial oxygen pressure, 
low pH and high osmolality4,19. This results in a range of renal manifestations that can include:  
chronic renal failure, hematuria, renal medullary carcinoma and nocturnal enuresis4,19.  
2.4.8 Avascular Necrosis 
Avascular necrosis of the joints occurs in adolescent and young adult SCD patients20. This is a 
bone disorder of the hips, femoral and humeral heads that is caused by temporary or permanent 
blood loss due to vaso-occlusive events20. Most patients that present with avascular necrosis 
experience progressive deterioration of the femoral head and require a total hip arthroplasty20.  
Fifty percent of all patients with SCD will develop avascular necrosis by 35 years of age20. 
2.4.9 Cerebrovascular Accidents (CVA) 
Cerebrovascular accidents (strokes) are a leading cause of death in both pediatric and adult 
patients with SCD19,21. Eleven percent of all patients will have a stroke by 20 years of age. Once 
a stroke has occurred, the risk for recurrence is greater than 60%4,5.  Silent cerebral infarcts (SCI) 
are the most common form of CVA occurring in 22% of all children with SCD22. 
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2.4.10 Proliferative Sickle Retinopathy (PSR) 
The physiological changes that occur in the RBCs of SCD patients lead to damage in the blood 
vessels of the eye23.  This results in the formation of new blood vessels that are weaker and prone 
to rupture23.  Retinopathy can compromise the vision of SCD patients.  Studies have shown that 
the frequency of PSR within SCD patients varies depending of the patient’s genotype and can be 
as high as 70%23. 
2.5 PAIN IN SICKLE CELL DISEASE 
“Sickle Cell pain is unique and, like other types of pain, is a complex human experience that is 
strongly affected not only by pathophysiologic factors but also by psychological, social, cultural 
and spiritual ones24.” Acute painful episodes are the most common clinical manifestations of 
SCD, resulting in 90% of hospital admissions among adult SCD patients25. While the exact 
sequence of events leading to a pain episode are not well understood, it is thought to be a 
continuous cycle where by vaso-occlusion results in tissue ischemia and damage, leading to a 
secondary inflammatory response, triggering the release of norepinephrine which ultimately 
leads to further tissue ischemia24.  
Studies have shown that pain episodes can be triggered by a wide range of factors 
including but not limited to: dehydration, stress, alcohol consumption, extreme temperatures, 
changes in humidity, menstrual cycle, infection, obstructive sleep apnea and cardiac or 
pulmonary impairments25–34.  The pain experienced in SCD is further complicated by its 
unpredictable nature.  Pain crises are known to vary in location, severity and duration.  
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Furthermore, it can become hard for healthcare professionals to accurately identify patients at the 
early stages of a pain crisis due to the fact that 50% of patients do not show any objective signs 
at the beginning stages of a pain episode24.  
2.5.1 Landmark Sickle Cell Pain Studies  
Two hallmark studies have been conducted to study prevalence of pain in SCD: the Cooperative 
Study of Sickle Cell Disease (CSSCD) and The Pain in Sickle Cell Epidemiology Study 
(PiSCES). The CSSCD study was a federally funded multicenter study that followed the natural 
history of SCD in a total of 3,578 patients over a 10-20 year time period6,35.  Among many other 
issues, researchers wanted to identify possible events that led to the onset of a pain crisis. The 
PiSCES study was a prospective cohort study conducted in the state of Virginia that asked 232 
SCD patients to complete daily pain diaries over a six month time period to determine the 
correlation between the pain they were experiencing and their response to this pain3. 
While these studies are informative, they both have weaknesses that need to be 
addressed.  The main weakness of the CSSCD study is that the classification of pain episodes 
was limited to “the occurrence of pain in the extremities, back, abdomen, chest or head that 
lasted at least 2 hours led to a clinic visit and could not be explained except by SCD6,35.”  This is 
a weakness because 39% of participants in this study never sought medical attention and so were 
classified as having no pain episodes6.  This may be an underrepresentation of the pain episodes 
in this population, due to the fact that the study does not take into account self-treated pain 
episodes. Another weakness of the CSSCD study is that it counted pain episodes that occurred 
within a 2 week timeframe as one episode6,35.  Based on this classification, 74 patients were 
excluded from the final analysis due to the fact that they presented with  “greater than 10 closely 
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spaced pain episodes6.”  The PiSCES study sought to address these weaknesses by utilizing daily 
pain diary journaling, allowing the patient to assess whether or not they were experiencing a pain 
episode3.  
 While the CSSCD study showed an average of less than 1 pain episode per year, the 
PiSCES study has shown this to be a gross underestimate of pain episodes.  Rather, the PiSCES 
study demonstrated that patients reported experiencing pain 54.5% of the time but only sought 
medical attention 3.5% of the time3,6,35.   The PiSCES study is limited by the accuracy of 
journaling and the reliance on patients to mail in monthly submissions. It has been suggested that 
patients may misrepresent their compliance by backfilling or forward filling diary entries. With 
no mechanism to validate when each entry was completed, one can call into question the validity 
of the data collected. 
2.5.2 Compliance in Pain diaries 
Patient self-reports have become a vital aspect to clinical research with 25% of all clinical and 
pharmaceutical trials utilizing some form of a diary 36. Many have expressed concern in the 
validity of paper diaries due to the inability to validate patient reported compliance.  In 2003, 
Stone et al. utilized paper diaries equipped with photo sensory technology to investigate the 
validity of patient reported compliance36.  During the study, patients were asked to log their pain 
levels three times daily in either a paper diary or an electronic diary36.   Participants were 
informed that compliance would be based on whether the participant made an entry within the 
fifteen minutes surrounding each of the three designated time periods (10:00 am, 4:00 pm, 8:00 
pm)36. While the reported compliance rate in the paper diary group was comparable to that of the 
electronic diary group (90.5% vs. 93.6% respectively) the actual compliance, based on photo 
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sensory data, was determined to be only 10.9%36.  This data suggests that 75-80% of dates and 
times listed in the paper diary entries were falsified by backfilling or forward filling36. 
This has lead to a push in the research community to find a tool that would allow for the 
validation of patient reports37–40.  Many companies now offer handheld devices that provide an 
electronic time stamp for each entry and allow researchers to set desired perimeters such as how 
often and when the patient can enter data. The downside to this technology is that it can be very 
expensive with start up costs and rental fees ranging from $200 to $2,000 per device39.   
2.6 USE OF MOBILE PHONES IN US TEENS 
The use of cellular phones have become an integral part of the lives of American teenagers with 
75% of all 12-17 year-olds now owning cell phones41. The use of these mobile devices allow 
teenagers to keep in touch with family and friends, coordinate their schedules, browse the 
internet, send emails and entertain themselves. Studies have shown that 41% of teens from low-
income households (income less than $30,000 annually) use their cell phones to access the 
Internet41. This influx in technology within the general public provides clinical investigators with 
an inexpensive resource that was not available a few decades ago. Researchers have been given 
an opportunity to design research tools that can be seamlessly incorporated into patients’ daily 
lives.  
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3.0  SPECIFIC AIMS 
3.1 AIM #1: STUDY FEASIBILITY 
To determine the feasibility of obtaining pain severity scores from adolescents and young adults 
using a web based tool. 
3.2 AIM #2: PATIENT SATISFACTION 
To determine patient satisfaction with a web based pain monitoring application. 
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4.0  METHODS AND PROCEDURES 
4.1 WEBSITE DESIGN 
Data Warehouse Consultants was commissioned to design a web-based application and database 
that allowed for pain measurements to be electronically time stamped and recorded on a secure 
SQL server 2008 database. The application consisted of several basic components: the patient 
website and database and the administrative website. 
4.1.1 Patient Website and Database 
This website was available on the Internet and asked participants to appraise their pain level by 
use of a Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (extreme pain) (Figure 6). 
For security reasons, participants were assigned a unique patient identification number (UPIN), 
which enabled them to log into the system without referencing any personal health information. 
Pain measurements were electronically time stamped and all information was filtered to ensure 
the protection of patient sensitive information. Only non-specific patient information was stored 
in the database. 
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 Figure 2: Depiction of Web-Based Application 
4.1.2 Administrative Website 
 This website was created for the project administrators to manage the participants in the study.  
It contained web forms for enrolling patients in the study, participation statistics and provided 
authorized team members with each participant’s contact information and pain plans.   This 
website was available only on the CHP intranet which allowed it to leverage the existing CHP 
security infrastructure to maintain the highest levels of security for this type of application.  The 
database for this application extracts data directly from the patient database so that no direct 
access to patient-sensitive data is possible via the Internet.    
4.2 PARTICIPANT RECRUITMENT 
Patients attending The Children’s Hospital of Pittsburgh of UPMC Sickle Cell Clinic were 
approached and considered for enrollment into the University of Pittsburgh IRB approved study 
#PRO10110214 based on the following criteria. 
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 4.2.1 Inclusion Criteria 
1. Patients with SCD 
2. Patients ranging from 12-22 years of age, on date of enrollment 
3. Patients who attend the Children’s Hospital of Pittsburgh’s Sickle Cell Clinic 
4. Patients who have access to a cellular telephone with Internet capability or computer 
with internet access 
4.2.2 Exclusion Criteria 
1. Sickle Cell patients less than 12 yrs of age or older than 22 yrs of age, on date of 
enrollment 
2. Sickle Cell patients who do not attend the Children’s Hospital of Pittsburgh’s Sickle 
Cell Clinic 
3. Sickle Cell patients who do not have access to a cellular phone with internet 
capabilities or a computer with internet access 
4. Sickle Cell patients with severe medical complications 
4.2.3 Ethical Considerations 
Every possible effort was taken to include gender and racial equality into this study. Both female 
and minority participants were eligible for this study and encouraged to participate. 
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4.3 CONSENT PROCESS 
All eligible participants, as specified by the above criteria, were fully briefed on the criteria, risks 
and benefits of the study.  They were provided with an IRB approved consent form (Appendix A 
and Appendix B) that fully described the study and provided the participant with ample 
information to make an informed decision regarding their participation in the study.  Subjects 
were assured that their participation was voluntary and that withdrawal from the study would not 
jeopardize current or future treatment.  
Formal consent was obtained prior to any involvement in the study. The participant was 
provided with a copy of the consent form and the original consent was retained as part of the 
study records (Appendix A and B). 
4.4 COMPENSATION 
Participants were asked to access and enter their pain levels, on a scale of 0-10, three times a day 
on the web-based application. A minimum of 4 hours was required between entries. All 
participants in the study have been compensated in the form of a WePay® gift card. Participants 
who successfully reported 3 consecutive days worth of web entries had $1.50 applied to their gift 
card. After one week’s worth of consecutive web entries participant’s compensation rate was 
increased to $4.50 and after a month’s worth of consecutive web entries compensation were 
increased to $19.50. If at any point the participant skipped an entry period, they were reverted 
back to the base compensation rate of $1.50, while still retaining the existing balance on their gift 
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card.  Based on this scale, a participant who completed all entries over the one-year study time 
period would have the potential of earning $231.00 in the form of a WePay gift card. 
4.5 PAIN INTERVENTION 
Each participant worked with team members to define their individual baseline pain level, the 
level of pain at which they would like medical intervention and their self-defined pain crisis 
level.  When a participant logged pain levels of 5.0 through 10.0 it resulted in the generation of 
an email/text message, alerting authorized team members of potential pain crises.  An authorized 
team member contacted participants, when they reported pain levels equal to or greater than their 
previously defined medical intervention level. Participants were asked to provide details 
regarding the type and location of their pain, treatments they had tried and whether these 
treatments alleviated their pain. All contacted participants were offered the opportunity to speak 
with a medical professional that would provide further instructions on how to alleviate their pain.  
4.6 SATISFACTION SURVEY 
Six months into the study all participants were asked to complete a brief 4-point likert scale 
survey (Appendix C), which consisted of eleven questions.   These questions addressed topics 
such as the user-friendliness of the application, the impact the study had on the participant’s 
everyday life and their behavioral patterns. 
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4.7 STATISTICAL ANALYSIS 
All data manipulations and descriptive statistics were performed with SAS 9.3. The frequency 
and percentages for pain entries were computed across all data, per patient and per day. The 
median across pain entries per patient was computed. A daily pain score was summarized as the 
maximum pain entry reported in a single day. The pain score was categorized into 3 groups: no 
pain for a pain score of 0, pain for pain scores 1-7 and crisis for pain scores 8-10. Frequency of 
pain days (days with a daily pain score of 1-10) and days without pain (a score of 0) were 
compiled and percentages computed. Means of daily pain levels were computed across all days 
with pain score submission, as well as across all pain days. 
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5.0  RESULTS 
5.1 POPULATION DEMOGRAPHICS 
Two hundred and fifty three patients attend the Sickle Cell clinic at The Children’s Hospital of 
Pittsburgh of UPMC. One hundred and thirty of these patients were between 12 years and 22 
years of age during the study enrollment period.  Of these 130 patients, 60 (46%) attended a 
clinic appointment between March 17, 2011 and September 19, 2011. Thirty-one (52%) of the 60 
patients approached declined to participate in the study. Reasons for not participating in the 
study included: lack of access to a computer or mobile device; parental restriction due to 
behavioral issues; and perceived burden of logging levels three times daily.  
Twenty-nine patients (48%) were enrolled in the web-based study. Seven of these 
patients (24%) did not log any pain score for the duration of the study.  Of the remaining 22 
patients (76%), we excluded one (5%) because they consistently disregarded the time restriction 
between pain entries. The data gathered from the remaining 21 patients served as the analysis 
sample.  
Table 2 lists the population demographics of the analysis sample (n=21).    
Approximately two-thirds of the study participants were female (66.7%), with a median age of 
17 years.  Fifty-two percent of participants (n=11/21) were diagnosed with Sickle Cell Anemia, 
29% (n=6/21) of participants were diagnosed with Hemoglobin SC, 14% (n=3/21) were 
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diagnosed with Hemoglobin Sβ+ and the remaining 5% (n=1/21) of participants were diagnosed 
with Hemoglobin S-HPFH.   
         Table 2: Participant Demographics 
Genotype                      n                 %          
Hb SS 11 52.4 
Hb SC 6 28.6 
Hb Sβ+ 3 14.3 
        Hb S-HPFH 1 4.8 
Gender                        n                   % 
Female 14 66.7 
Male 7 33.3 
Age 
Median     17  
Std Dev     2.37  
Youngest     14  
Oldest     21  
 
5.2 STUDY FEASIBILITY 
 
A total of 4,981 pain entries (129 patient days) were included in this analysis. The median 
number of pain scores entered was 275, representing 71% of requested scores.  Figure 7 depicts 
the distribution of pain entries based on submission type.  More than half (63%) of all scores and 
86% of all patient initiated submissions, were entered using the online application. Ten percent 
of all scores, 14% of all patient initiated submissions, were received by text message due to the 
participant’s inability to log onto the website. Twenty-seven percent of all scores were retrieved 
from electronic hospital records due to the patient being hospitalized for a Sickle Cell related 
complication.  
 23 
                 Figure 3: Distribution of Entries by Submission Type 
 
 
Figure 8 represents the number of occurrences where a participant reported pain entries 
one, two, or three times daily. Over the course of 129 days, participants reported pain levels three 
times daily 67% of the time. Participants reported twice daily 21% of the time and once daily 
12% of the time. 
 
                Figure 4: Frequency of Pain Entries per Day 
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5.3 ANALYSIS OF PAIN 
 
Figure 9 depicts the breakdown of each individual participant’s pain experience. Throughout the 
length of the study (n=129), a quarter of all participants reported some level of pain, with the 
highest mean pain level reported as an 8. One participant never reported experiencing any level 
of pain.  
 
                Figure 5: Individual Mean Pain Intensity 
 
Pain entries were broken down into three ordinal, mutually exclusive categories of No 
“Pain”, “Pain-No Crisis” and “Crisis”.  The category of No pain was associated with a pain score 
of 0.  The “Pain-No Crisis” category was associatd with a pain score of 1-7 and the “Crisis” was 
associated with a pain score of 8-10. The “Crisis” category was further broken into “Crisis-No 
Utilization” and “Crisis-Utilization” based on whether the participant’s pain crisis was associated 
with an unplanned healthcare utilization.  Figure 10 depicts the percentage of patient days 
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(n=129) as broken down into these 4 exclusive categories. Patients reported no pain 23.4% of 
129 analyzed patient days. This means that the participants were in pain 86.6% of the analyzed 
days. On 64.4% of these days participants reported pain without crisis. Participants reported pain 
with crisis 12.2% of the analyzed days but only sought medical attention 8.5% of the time. 
 
   
                Figure 6: Frequency of Pain Episodes 
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5.4 SATISFACTION SURVEY 
 
Telephone interviews were conducted to provide a 5 month interim analysis regarding 
participants overall satisfaction with the web-based application. The questions addressed three 
keys areas of interest: the user-friendliness of the web-based application, participant’s immediate 
compliance with online monitoring and the impact of the web-based application on the 
participant. Responses were based on a 4-point likert scale with 1 indicating no/not at all, 2 
indicating somewhat, 3 indicating considerably and 4 indicating yes/always.  
All twenty-one participants were contacted, with 12 participants (57%) responding. Table 
3 reports the results of the survey. Possible reasons for not responding to the survey may include: 
inability to be reached by telephone, discontinuation of phone service and lack of interest in 
participating in survey.  Forty-two percent (n=5/12) of all respondents indicated that they did not 
have trouble accessing the web-based application from their cellular phone. Eighty-three percent 
(n=10/12) of respondents reported that they had no difficulty in viewing or answering the 
application from their cell phone or electronic device. All respondents indicated that the 
instructions were clear to them. Seventy-five percent of respondents (n=9/12) indicated that 
receiving text message reminders were beneficial in the timely submission of pain entries.   
All respondents reported that they did not feel the study was a burden and would agree to 
participate again in a comparable study. Roughly half of all respondents (58%) indicated that this 
study influenced their life, by identifying patterns in their pain. Sixty-seven percent of 
respondents (n=8/12) reported that the application assisted them in detecting early symptoms of a 
pain episode and 75% of respondents (n=9/12) felt that the feedback they received from the 
medical team assisted them in preventing a pain episode.  
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 Table 3: Satisfaction Survey Results 
N= 11 
1 
(no /not at all)
 
2 
(somewhat) 
 
3 
(considerably) 
 
4 
(yes/always) 
 
User‐friendliness of the Web‐Based Application  
Did you have trouble accessing the application 
from your cell phone? 
5  2  1  4 
Did you have difficulties reading or viewing the 
application from your cell phone/ electronic 
device? 
10  1  0  1 
Could you conveniently answer the application 
from your cell phone/ computer? 
1  1  0  10 
Were the instructions clear to you?  0  0  0  12 
Immediate compliance with online monitoring 
How often did you fill out the application 
directly after being prompted?
 1  2  4  5 
Impact of Web‐Based Application 
Did you feel that participating in this study was 
a burden? 
12  0  0  0 
Did the study influence your life?  3  2  1  6 
Was the number of times required to log onto 
the web‐based application annoying? 
9  3  0  0 
Would you agree to participate again in a 
comparable study? 
0  0  0  12 
Web‐based Application support of behavioral training 
Did the application help detect early symptoms 
of pain episodes? 
1  3  0  8 
Did the medical teams' feedback help you to 
take actions to prevent a pain episode? 
0  2  1  9 
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6.0  DISCUSSION 
The increase in the development of mobile devices with Internet capabilities has greatly 
impacted the realm of clinical research. Researchers can now utilize mobile devices in place of 
paper diaries to monitor participants.  This study set out to determine the feasibility of using a 
web-based tool to monitor pain scores of adolescents and young adults with SCD. While 33% (4 
out of 12 respondents) of respondents indicated that they could not access the application from 
their cellular phone, all four of these individuals were able to use other electronic devices (i.e. 
computer, iPod, etc.) to access the application. Three out of four of these respondents indicated 
that the lack of an adequate data package on their phone prevented them from being able to 
access the application. One participant had the appropriate data package in place but due to the 
age of their phone, had compatibility issues with accessing the application.  
While this is a small study, the data suggests that the use of a web-based application is 
both feasible and user-friendly with 86% of all patient-initiated submissions being entered via 
the web-based application. This suggests that this application provides an economical alternative 
to previously available handheld devices. As a means of addressing some of the initial 
connectivity issues, participants were provided with the option of texting pain scores to the 
research coordinator. Reasons for texting pain scores rather than accessing the web site directly 
included: cell phone compatibility issues, inaccessibility due to traveling and internet 
connectivity.  
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The second goal of this study was to determine patient satisfaction with a web-based pain 
monitoring application. The analysis is limited by the fact that nearly half (43%) of all 
participants did not respond to the satisfaction survey. Possible reasons for not responding to the 
survey may include: inability to be reached by telephone, discontinuation of phone service and 
lack of interest in participating in survey.  Of the 12 participants that responded, the majority 
(83%) felt that they could conveniently access the web-application and all respondents stated that 
the instructions were clear to, they did not feel that the study was a burden and they would agree 
to participate again in a comparable study.  
When comparing our findings with those of Smith et al., our data reinforces the results 
that were previously reported in the adult Sickle Cell population3. While Smith et al. found that 
patients were in pain 54.5% of analyzed patient days but only sought medical attention 3.5% of 
the time3, our data shows that participants were in pain 76.6% of analyzed patient days and 
sought medical attention 8.5% of the time.  This serves to further suggest that the use of a web-
based application has a viable place in the clinical research setting.   
Future plans include the expansion of the web-based application to incorporate Patient 
Report Outcome Measurement Information System (PROMIS®) and to encompass multiple 
Sickle Cell clinics nationwide.  PROMIS® was developed and validated by the NIH funded 
patient reported outcomes consortium and incorporates highly reliable and precise measurements 
of the effect of pain on a patient’s physical, mental and social well being.  
In conclusion, this study has successfully illustrated that the incorporation of a web-based 
application can be utilized to provide a more reliable monitoring of pain thresholds in the Sickle 
Cell population. The current data also suggests that participants were provided with invaluable 
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knowledge regarding their pain patterns and the recognition of symptoms indicative of an 
impending pain episode.  
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APPENDIX A 
MINOR PARTICIPANT CONSENT FORM 
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APPENDIX B 
ADULT PARTICIPANT CONSENT FORM 
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APPENDIX C 
PARTICIPANT SATISFACTION SURVEY 
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Participant Satisfaction Survey 
Please take a few moments to provide us with your feedback regarding your experience 
with the web-based application: 
 
 
 
 
 
User-friendliness of the Web-Based Application 
accessed by cell phone? N
o/
no
t 
  So
m
ew
ha
t 
    C
on
si
de
ra
bl
y 
  Ve
ry
 M
uc
h 
Did you have trouble accessing the application from 
your cell phone? 
 
         1           2            3          4 
Did you have difficulties reading or viewing the 
application from your cell phone/ electronic device? 
 
         1           2            3          4 
Could you conveniently answer the application from 
your cell phone/ electronic device? 
 
         1           2            3          4 
Were the instructions clear to you? 
 
         1           2            3          4 
Immediate compliance with online monitoring  
How often did you fill out the application directly after 
being prompted? 
 
         1           2            3          4 
Impact of Web-Based Application  
Did you feel that participating in this study was a 
burden? 
 
         1           2            3          4 
Did the study influence your life? 
 
         1           2            3          4 
Was the number of times required to log onto the web-
based application annoying? 
 
         1           2            3          4 
Would you agree to participate again in a comparable 
study? 
 
         1           2            3          4 
Web-Based Application support of behavioral 
training 
 
Did the application help detect early symptoms of a 
pain episode? 
 
         1           2            3          4 
Did the medical teams’ feedback help you to take 
actions to prevent a pain episode? 
         1           2            3          4 
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